LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

Search

Twist Bioscience Corp

Deschisă

SectorSănătate

49.93 2.21

Rezumat

Modificarea prețului

24h

Curent

Minim

47.67

Maxim

50.09

Indicatori cheie

By Trading Economics

Venit

-3.4M

-31M

Vânzări

4.7M

104M

Marjă de profit

-29.419

Angajați

979

EBITDA

-3.2M

-24M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+8.13% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

409M

3B

Deschiderea anterioară

47.72

Închiderea anterioară

49.93

Sentimentul știrilor

By Acuity

50%

50%

161 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Twist Bioscience Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 feb. 2026, 23:07 UTC

Câștiguri

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb. 2026, 23:01 UTC

Câștiguri

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb. 2026, 22:59 UTC

Câștiguri

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 feb. 2026, 22:42 UTC

Câștiguri

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 feb. 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 feb. 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 feb. 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 feb. 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 feb. 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 feb. 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24 feb. 2026, 23:16 UTC

Câștiguri

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 feb. 2026, 23:13 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 feb. 2026, 23:12 UTC

Câștiguri

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 feb. 2026, 23:10 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 feb. 2026, 23:10 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 feb. 2026, 23:08 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 feb. 2026, 23:07 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 feb. 2026, 22:52 UTC

Câștiguri

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb. 2026, 22:46 UTC

Câștiguri

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb. 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Warner Receives New Bid From Paramount -- 3rd Update

24 feb. 2026, 22:29 UTC

Câștiguri

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 feb. 2026, 22:28 UTC

Câștiguri

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 feb. 2026, 22:27 UTC

Câștiguri

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 feb. 2026, 22:27 UTC

Câștiguri

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 feb. 2026, 22:25 UTC

Câștiguri

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 feb. 2026, 22:24 UTC

Câștiguri

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 feb. 2026, 22:23 UTC

Câștiguri

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 feb. 2026, 22:22 UTC

Câștiguri

Woolworths Interim Dividend 45 Australian Cents/Share

24 feb. 2026, 22:22 UTC

Câștiguri

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 feb. 2026, 22:21 UTC

Câștiguri

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparație

Modificare preț

Twist Bioscience Corp Așteptări

Obiectiv de preț

By TipRanks

8.13% sus

Prognoză pe 12 luni

Medie 52 USD  8.13%

Maxim 58 USD

Minim 50 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTwist Bioscience Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

31.56 / 38.6884Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

161 / 351 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat